Eye

Eye - commissioning policies

Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.

The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Anti-vascular endothelial growth factors for use prior to vitrectomy in patients with proliferative diabetic retinopathy Bevacizumab for diabetic macular oedema Bevacizumab for the first line treatment of neovascular (wet) age related macular degeneration Botulinum Toxin A for the management of blepharospasm and the management of hemifacial spasm (see central nervous system commissioning policies, click here)
Patients diagnosed with blepharospasm should be advised to check with the Driver and Vehicle Licensing Agency (DVLA) the requirements for notification and assessment with regard to continuing their licence to drive. 
Cataract surgery (see surgery commissioning policies, click here)
To access the accompanying Clinical policy patient support information for the cataract surgery policy please click here.
Dexamethasone intravitreal implant (Ozurdex®) for the treatment of non-infectious posterior uveitis Meibomian cysts (Chalazia) guidance

Please note:  Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category. 

In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here

Consideration of treatment options for chronic eye conditions in the NHS

Please find two letters below regarding consideration of treatment options for chronic eye conditions in the NHS.

These have been sent to the Right Honourable Jeremy Hunt MP, Secretary of State for Health and Mr Simon Stevens, Chief Executive of NHS England.
Letter to Rt Hon Jeremy Hunt - consideration of treatment options for chronic eye conditions in the NHS Letter to Simon Stevens - consideration of treatment options for chronic eye conditions in the NHS

Rate this page